ALNYLAM PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.7 | $2.2 | $1.8 | $1.0 | $0.8 |
| Operating income | $0.5 | -$0.2 | -$0.3 | -$0.8 | -$0.7 |
| Net income | $0.3 | -$0.3 | -$0.4 | -$1.1 | -$0.9 |
| Cash Flow Statement | |||||
| Free cash flow | $0.5 | -$<0.1 | $<0.1 | -$0.6 | -$0.7 |
Shares outstanding 133.8M · Free float 99.5%
Annual filing data through FY ended December 31, 2025; float as of September 27, 2026.